Kapur, J;
Elm, J;
Chamberlain, JM;
Barsan, W;
Cloyd, J;
Lowenstein, D;
Shinnar, S;
Conwit, R;
Meinzer, C;
Cock, HR;
et al.
Kapur, J; Elm, J; Chamberlain, JM; Barsan, W; Cloyd, J; Lowenstein, D; Shinnar, S; Conwit, R; Meinzer, C; Cock, HR; Fountain, N; Connor, JT; Silbergleit, R
(2019)
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
NEW ENGLAND JOURNAL OF MEDICINE, 381.
pp. 2103-2113.
ISSN 0028-4793
https://doi.org/10.1056/NEJMoa1905795
SGUL Authors: Cock, Hannah Rutherford
|
PDF
Published Version
Available under License ["licenses_description_publisher" not defined]. Download (246kB) | Preview |
|
![]() |
PDF
Accepted Version
Restricted to Repository staff only Download (269kB) |
Abstract
Background The choice of drugs for patients with status epilepticus that is refractory to treatment with benzodiazepines has not been thoroughly studied. Methods In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents — levetiracetam, fosphenytoin, and valproate — in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines. The primary outcome was absence of clinically evident seizures and improvement in the level of consciousness by 60 minutes after the start of drug infusion, without additional anticonvulsant medication. The posterior probabilities that each drug was the most or least effective were calculated. Safety outcomes included life-threatening hypotension or cardiac arrhythmia, endotracheal intubation, seizure recurrence, and death. Results A total of 384 patients were enrolled and randomly assigned to receive levetiracetam (145 patients), fosphenytoin (118), or valproate (121). Reenrollment of patients with a second episode of status epilepticus accounted for 16 additional instances of randomization. In accordance with a prespecified stopping rule for futility of finding one drug to be superior or inferior, a planned interim analysis led to the trial being stopped. Of the enrolled patients, 10% were determined to have had psychogenic seizures. The primary outcome of cessation of status epilepticus and improvement in the level of consciousness at 60 minutes occurred in 68 patients assigned to levetiracetam (47%; 95% credible interval, 39 to 55), 53 patients assigned to fosphenytoin (45%; 95% credible interval, 36 to 54), and 56 patients assigned to valproate (46%; 95% credible interval, 38 to 55). The posterior probability that each drug was the most effective was 0.41, 0.24, and 0.35, respectively. Numerically more episodes of hypotension and intubation occurred in the fosphenytoin group and more deaths occurred in the levetiracetam group than in the other groups, but these differences were not significant. Conclusions In the context of benzodiazepine-refractory convulsive status epilepticus, the anticonvulsant drugs levetiracetam, fosphenytoin, and valproate each led to seizure cessation and improved alertness by 60 minutes in approximately half the patients, and the three drugs were associated with similar incidences of adverse events. (Funded by the National Institute of Neurological Disorders and Stroke; ESETT ClinicalTrials.gov number, NCT01960075. opens in new tab.)
Item Type: | Article | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | From New England Journal of Medicine, Kapur, J; Elm, J; Chamberlain, J; Barsan, W; Cloyd, J; Lowenstein, D; Shinnar, S; Conwit, R; Meinzer, C; Cock, HR; et al., Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus, 381, 2103-2113 Copyright © 2019 Massachusetts Medical Society. Reprinted with permission. | ||||||||||||||||||
Keywords: | 11 Medical And Health Sciences, General & Internal Medicine | ||||||||||||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Institute of Medical & Biomedical Education (IMBE) Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE ) |
||||||||||||||||||
Journal or Publication Title: | NEW ENGLAND JOURNAL OF MEDICINE | ||||||||||||||||||
ISSN: | 0028-4793 | ||||||||||||||||||
Dates: |
|
||||||||||||||||||
Publisher License: | Publisher's own licence | ||||||||||||||||||
Projects: |
|
||||||||||||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/111387 | ||||||||||||||||||
Publisher's version: | https://doi.org/10.1056/NEJMoa1905795 |
Statistics
Actions (login required)
![]() |
Edit Item |